Andelyn Biosciences ("Andelyn"), a leading US-based patient-focused cell and gene therapy Contract Development and ...

Ultragenyx Pharmaceutical RARE announced that the European Medicines Agency (EMA) has validated its Marketing Authorization ...

Gene therapy has opened new possibilities for treating and potentially curing diseases by addressing their underlying genetic ...

The US FDA has approved Ultragenyx Pharmaceutical’s rebisufligene etisparvovec (Fayuvi) for paediatric patients with ...

Successful production of reference protein advances proprietary protein engineering and gene therapy development ...

The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma ...

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with ...

CRISPR is one of this generation’s most profound innovations, with the potential to fundamentally alter the realm of modern ...

Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. BOSTON — A medicine increasingly used to ...

Regulatory support, biotech advances and R&D partnerships drive Japan’s market, led by cell therapies and pre-commercial manufacturing.Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Japan Cell and Gene ...

New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher ...